AR053671A1 - METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOL DERIVATIVES - Google Patents

METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOL DERIVATIVES

Info

Publication number
AR053671A1
AR053671A1 ARP060100402A AR053671A1 AR 053671 A1 AR053671 A1 AR 053671A1 AR P060100402 A ARP060100402 A AR P060100402A AR 053671 A1 AR053671 A1 AR 053671A1
Authority
AR
Argentina
Prior art keywords
methods
dosage forms
derivatives
side effects
reduce
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/051,060 external-priority patent/US20050208132A1/en
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR053671A1 publication Critical patent/AR053671A1/en

Links

Abstract

Formas de dosificacion y métodos que comprende derivados de benzisoxazol. Más específicamente, se revelan formas de dosificacion, métodos y usos de derivados de benzisoxazol que reducen sustancialmente o eliminan sustancialmente ciertos efectos secundarios del derivado de benzisoxazol cuando se dosifican a un paciente.Dosage forms and methods comprising benzisoxazole derivatives. More specifically, dosage forms, methods and uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivative when dosed to a patient are disclosed.

ARP060100402 2005-02-04 2006-02-03 METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOL DERIVATIVES AR053671A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/051,060 US20050208132A1 (en) 2002-07-29 2005-02-04 Methods and dosage forms for reducing side effects of benzisozazole derivatives

Publications (1)

Publication Number Publication Date
AR053671A1 true AR053671A1 (en) 2007-05-16

Family

ID=38048170

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100402 AR053671A1 (en) 2005-02-04 2006-02-03 METHODS AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOL DERIVATIVES

Country Status (4)

Country Link
AR (1) AR053671A1 (en)
PE (1) PE20060997A1 (en)
TW (1) TW200638936A (en)
UY (1) UY29363A1 (en)

Also Published As

Publication number Publication date
TW200638936A (en) 2006-11-16
UY29363A1 (en) 2006-08-31
PE20060997A1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
CO2017001994A2 (en) Active compounds towards bromodomains
PE20191474A1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CL2008001626A1 (en) Compounds derived from fused heterocycles, a pharmaceutical agent that comprises them and their use in the prophylaxis and treatment of cancer.
UY30846A1 (en) OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
CL2016002589A1 (en) Use of compound genz-112638 (eliglustat), glucosylceramide synthase inhibitor, in the treatment of gaucher disease and fabry disease (divisional application 201201348).
CL2011000101A1 (en) Compounds derived from substituted pyridazine; hedgehog and smo signaling inhibitors; pharmaceutical composition; and use for the treatment of disorders or syndromes associated with hyperproliferative diseases.
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
CL2007003686A1 (en) COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION.
UY31497A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
CL2016000117A1 (en) Autotaxin inhibitors comprise a heteroaromatic ring-benzylamine basic cycle
CL2013001338A1 (en) Compounds derived from substituted benzothiene-pyridines, hiv replication inhibitors; pharmaceutical composition that includes them; pharmaceutical combination; pharmaceutical kit; and its use for the treatment of hiv.
CL2011000454A1 (en) Compounds derived from picolinamide, pim kinase inhibitors, associated with tumorigenesis; pharmaceutical composition that includes them; and its use in the treatment of cancer.
CL2007003520A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
GT200900283A (en) "COMBINATION THERAPY WITH A COMPOUND ACTING AS AN ADP PLAQUETARY RECEPTOR INHIBITOR".
CL2009000483A1 (en) Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
ES2352576T8 (en) INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION.
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
NO20075068L (en) Lipocalinprotein
CL2008003473A1 (en) Heterocycle substituted phenylpiperidine derivative compounds; preparation procedure; pharmaceutical composition comprising it; and use in the treatment of cardiovascular, thromboembolic and tumor disorders; in vitro uses.
CL2016002835A1 (en) "Compounds derived from pladienolide with a pyridinic moiety; pharmaceutical composition comprising them; and its use in cancer treatment. ” pct
CL2008002369A1 (en) Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
DOP2009000165A (en) DERIVATIVES OF REPLACED OXINDOL, MEDICATIONS THAT UNDERSTAND AND USE THEMSELVES
CL2008002049A1 (en) Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
CL2017001904A1 (en) Composition for the treatment of hepatic veno-occlusive disease.
CL2007003251A1 (en) Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure